ArticleMolecular imaging and biology2019
Differentiation of Malignant and Benign Head and Neck Tumors with Amide Proton Transfer-Weighted MR Imaging.
Article in Molecular imaging and biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Detection of breast cancer lesions using APT weighted MRI: a systematic review.Journal of translational medicine · 2025Pooled it
- The Environmental Impact of Medical Imaging Agents and the Roadmap to Sustainable Medical Imaging.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Synthetic MRI and amide proton transfer-weighted MRI for differentiating between benign and malignant sinonasal lesions.European radiology · 2024Article
- Image quality assessment and feasibility of three-dimensional amide proton transfer-weighted imaging for hepatocellular carcinoma.Quantitative imaging in medicine and surgery · 2024Article
- Label-Free Chemically and Molecularly Selective Magnetic Resonance Imaging.Chemical & biomedical imaging · 2023Review
- Article
- Baseline Amide Proton Transfer Imaging at 3T Fails to Predict Early Response to Induction Chemotherapy in Nasopharyngeal Carcinoma.Frontiers in oncology · 2022Article
- Dynamic Change of Amide Proton Transfer Imaging in Irradiated Nasopharyngeal Carcinoma and Related Histopathological Mechanism.Molecular imaging and biology · 2021Article
- A Brief History and Future Prospects of CEST MRI in Clinical Non-Brain Tumor Imaging.International journal of molecular sciences · 2021Review
- Feasibility evaluation of amide proton transfer-weighted imaging in the parotid glands: a strategy to recognize artifacts and measure APT value.Quantitative imaging in medicine and surgery · 2021Article
- Differentiating malignant from benign salivary gland lesions: a multiparametric non-contrast MR imaging approach.Scientific reports · 2021Article
- Pre-treatment amide proton transfer imaging predicts treatment outcome in nasopharyngeal carcinoma.European radiology · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
purposeTo prospectively evaluate the feasibility and capability of amide proton transfer-weighted (APTw) imaging for the characterization of head and neck tumors. PROCEDURES: Twenty-nine consecutive patients with suspected head and neck tumors were enrolled in this study and underwent APTw magnetic resonance imaging (MRI) on a 3.0-T MRI scanner. The patients were divided into malignant (n = 16) and benign (n = 13) groups, based on pathological results. A map of magnetization transfer ratio asymmetry at 3.5 ppm [MTR
resultsThe intraclass correlation coefficients of the malignant and benign groups were 0.96 and 0.90, respectively, which indicated a good interobserver agreement. MTR
conclusionsAPTw MRI is feasible for use in the head and neck tumors and is a valuable imaging biomarker for distinguishing malignant from benign lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.